vimarsana.com

Latest Breaking News On - Chiesi farmaceutici - Page 5 : vimarsana.com

Sanofi to buy Inhibrx in deal worth up to $2.2B

Sanofi Commits $1.7B to Buy an Entire Company, But Wants Just a Single Drug

Sanofi is acquiring Inhibrx to get its hands on a drug candidate in pivotal testing for the protein deficiency alpha-1 antitrypsin deficiency, which leads to lung and liver problems. Inhibrx’s remaining assets will be spun out into a new company.

United-states
America
Chiesi-farmaceutici
Phouman-ashrafian
Mark-lappe
European-medicines-agency
California-based-inhibrx
North-america
European-medicines
Weight-loss
Obesity
Verweight

Life sciences a rare bright spot in muted Irish M&A activity last year - EY

Deal volumes in the Republic were down in 2023 but in value terms were up nearly 600 per cent year on year, according to EY analysis

Ireland
Italy
Irish
Italian
Aidan-meagher
Amryt-pharma
Chiesi-farmaceutici
Key

Life sciences mergers and acquisitions leap in value to €1.5bn

The value of mergers and acquisitions (M&A) activity in the life sciences ­sector in Ireland rose to €1.5bn last year, a jump of 596pc compared with 2022.

Dublin
Ireland
Irish
Chiesi-farmaceutici
Fergal-mcaleavey
Aidan-meagher
Amryt-pharma
Pfizer
Shorla-oncology
Vivasure-medical
Luma-vision
Bluedrop-medical

Value of M&A in Irish life sciences hit €1.5bn in 2023

Value of M&A in Irish life sciences hit €1.5bn in 2023
rte.ie - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from rte.ie Daily Mail and Mail on Sunday newspapers.

Ireland
Irish
Chiesi-farmaceutici
Fergal-mcaleavey
Aidan-meagher
Amryt-pharma
Head-of-life-sciences
Pfizer
Vivasure-medical
Neuromod-devices
Bluedrop-medical
Tax-partner
© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.